Logo

Fighting Cancer
with Precision Innovation

Our cancer targeting
NV-VPAC1™ benefits the patient, physician, and insurer, by making cancer diagnosing and therapy more accurate and affordable than ever before.

Targeting Diagnostic Needs 

NuView Life Sciences is developing a new class of targeted radiopharmaceuticals that can be used to diagnose and treat more types of cancer with greater precision and effectiveness. This patented technology has the potential to revolutionize the way cancer is treated, ensuring that NuView is positioned to be a leader in the field of precision oncology.


Our patented NV-VPAC1 peptide may be used to detect, diagnose, and treat most types of cancer including bladder, brain, breast, cervical, colorectal, pancreatic, and prostate cancer.

The NV-VPAC1™ Difference

In Vivo Diagnostic

NV-VPAC1 can be used as a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer. This PET scan improves the image-based diagnosis of breast cancer and could reduce the necessity of a breast biopsy by up to 50%. 


In Vitro Precision Diagnostic

NV-VPAC1 can be used to confirm cancer in an in vitro lab test. It binds to the VPAC1 receptor, which is overexpressed only on the surface of cancer cells. When it binds to the VPAC1 receptor, it emits a fluorescent signal. This signal can be detected by a laboratory assay to confirm the presence of cancer. 


A Delivery System for Radioisotopes

The theranostics application is revolutionary. The NV-VPAC1 peptide can be the delivery system for different isotopes. It can be used to deliver Copper-64 (Cu-64) for diagnostic imaging, and Copper-67 (Cu-67), a beta emitter to specifically treat the cancer. This paired Theranostics approach allows the physician to diagnose and localize the cancer, and subsequently visualize where the therapy is delivered, and enhance monitoring response to therapy. 


NVLS Products

In Vitro Diagnostics

AN IN VITRO DIAGNOSTIC KIT THAT MAY BE USED FOR DETECTING SHED PROSTATE AND BLADDER CANCER CELLS IN VOIDED URINE


In Vivo Diagnostics

A POSITRON EMISSION
TOMOGRAPHY (PET) IMAGING
AGENT FOR THE IN VIVO
DIAGNOSIS OF BREAST AND
PROSTATE CANCER


Theranostics

NuView is preparing to expand its portfolio for Theranostics applications using the NV-VPAC1 peptide analog...

NVLS Management Team

Together, they are furthering NuView Life Science’s mission: to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.

NVLS IN the NEWS

NuView Life Sciences Provides Corporate Update On NV-VPAC1 Theranostic For Breast Cancer  10.5.22

Press Release

PARK CITY, UT  NuView Life Sciences, Inc ("NuView", the "company"), is a clinical stage precision oncology company focusing on innovative approaches, such as theranostics, to diagnose and treat cancer.  read more


Targeting VPAC1 Receptors For Imaging Glioblastoma  1.25.22

Research Article

Malignant glioblastoma (MG) is the most common primary tumor of the cerebral hemisphere [1]. Glioblastoma multiforme, among them, is highly malignant and present poor prognosis. Despite the advances in treatment of MG, the disease remains largely incurable [2, 3].
read more


NuView Life Sciences Creates Subsidiary For Latin American Market  11.7.21

Press Release
PARK CITY, UT   NuView Life Sciences, Inc (“NuView”, the “company”), a clinical-stage oncology company focusing on innovative approaches to diagnose and treat cancers establishes NuView LATAM (“NV-LATAM”) in Mexico City.     read more


Share by: